메뉴 건너뛰기




Volumn 19, Issue 12, 2018, Pages 1579-1589

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AXITINIB; BENDAMUSTINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIRAPARIB; NIVOLUMAB; OBINUTUZUMAB; PACLITAXEL; PEMBROLIZUMAB; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

EID: 85058593629     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30608-9     Document Type: Article
Times cited : (822)

References (31)
  • 1
    • 84927150740 scopus 로고    scopus 로고
    • Immune checkpoint blockade in cancer therapy
    • Postow, MA, Callahan, MK, Wolchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
    • (2015) J Clin Oncol , vol.33 , pp. 1974-1982
    • Postow, M.A.1    Callahan, M.K.2    Wolchok, J.D.3
  • 2
    • 85045378539 scopus 로고    scopus 로고
    • Cancer immunotherapy using checkpoint blockade
    • Ribas, A, Wolchok, JD, Cancer immunotherapy using checkpoint blockade. Science 359 (2018), 1350–1355.
    • (2018) Science , vol.359 , pp. 1350-1355
    • Ribas, A.1    Wolchok, J.D.2
  • 3
    • 84994144982 scopus 로고    scopus 로고
    • Fulminant myocarditis with combination immune checkpoint blockade
    • Johnson, DB, Balko, JM, Compton, ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
    • (2016) N Engl J Med , vol.375 , pp. 1749-1755
    • Johnson, D.B.1    Balko, J.M.2    Compton, M.L.3
  • 4
    • 85042943560 scopus 로고    scopus 로고
    • Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
    • Moslehi, JJ, Salem, JE, Sosman, JA, Lebrun-Vignes, B, Johnson, DB, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, 391, 2018, 933.
    • (2018) Lancet , vol.391 , pp. 933
    • Moslehi, J.J.1    Salem, J.E.2    Sosman, J.A.3    Lebrun-Vignes, B.4    Johnson, D.B.5
  • 5
    • 85042935565 scopus 로고    scopus 로고
    • Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity
    • Escudier, M, Cautela, J, Malissen, N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136 (2017), 2085–2087.
    • (2017) Circulation , vol.136 , pp. 2085-2087
    • Escudier, M.1    Cautela, J.2    Malissen, N.3
  • 6
    • 85043452821 scopus 로고    scopus 로고
    • Myocarditis in patients treated with immune checkpoint inhibitors
    • Mahmood, SS, Fradley, MG, Cohen, JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
    • (2018) J Am Coll Cardiol , vol.71 , pp. 1755-1764
    • Mahmood, S.S.1    Fradley, M.G.2    Cohen, J.V.3
  • 7
    • 53849138066 scopus 로고    scopus 로고
    • VigiBase, the WHO global ICSR database system: basic facts
    • Lindquist, M, VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42 (2008), 409–419.
    • (2008) Drug Inf J , vol.42 , pp. 409-419
    • Lindquist, M.1
  • 8
    • 0031871338 scopus 로고    scopus 로고
    • A Bayesian neural network method for adverse drug reaction signal generation
    • Bate, A, Lindquist, M, Edwards, IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54 (1998), 315–321.
    • (1998) Eur J Clin Pharmacol , vol.54 , pp. 315-321
    • Bate, A.1    Lindquist, M.2    Edwards, I.R.3
  • 9
    • 84862216660 scopus 로고    scopus 로고
    • Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
    • Noren, GN, Hopstadius, J, Bate, A, Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22 (2013), 57–69.
    • (2013) Stat Methods Med Res , vol.22 , pp. 57-69
    • Noren, G.N.1    Hopstadius, J.2    Bate, A.3
  • 11
    • 4544368008 scopus 로고    scopus 로고
    • The reporting odds ratio and its advantages over the proportional reporting ratio
    • Rothman, KJ, Lanes, S, Sacks, ST, The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13 (2004), 519–523.
    • (2004) Pharmacoepidemiol Drug Saf , vol.13 , pp. 519-523
    • Rothman, K.J.1    Lanes, S.2    Sacks, S.T.3
  • 12
    • 85049141577 scopus 로고    scopus 로고
    • Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors
    • Grouthier, V, Lebrun-Vignes, B, Glazer, AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart 104 (2018), 1859–1863.
    • (2018) Heart , vol.104 , pp. 1859-1863
    • Grouthier, V.1    Lebrun-Vignes, B.2    Glazer, A.M.3
  • 13
    • 85040654063 scopus 로고    scopus 로고
    • Immune-related adverse events associated with immune checkpoint blockade
    • Postow, MA, Sidlow, R, Hellmann, MD, Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378 (2018), 158–168.
    • (2018) N Engl J Med , vol.378 , pp. 158-168
    • Postow, M.A.1    Sidlow, R.2    Hellmann, M.D.3
  • 15
    • 85047095751 scopus 로고    scopus 로고
    • Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
    • Conforti, F, Pala, L, Bagnardi, V, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. Lancet Oncol 19 (2018), 737–746.
    • (2018) Lancet Oncol , vol.19 , pp. 737-746
    • Conforti, F.1    Pala, L.2    Bagnardi, V.3
  • 16
    • 85043306908 scopus 로고    scopus 로고
    • Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
    • Wu, Y, Ju, Q, Jia, K, et al. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Cancer 143 (2018), 45–51.
    • (2018) Int J Cancer , vol.143 , pp. 45-51
    • Wu, Y.1    Ju, Q.2    Jia, K.3
  • 17
    • 0035846991 scopus 로고    scopus 로고
    • Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
    • Nishimura, H, Okazaki, T, Tanaka, Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001), 319–322.
    • (2001) Science , vol.291 , pp. 319-322
    • Nishimura, H.1    Okazaki, T.2    Tanaka, Y.3
  • 18
    • 85042198550 scopus 로고    scopus 로고
    • Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology
    • Varricchi, G, Galdiero, MR, Tocchetti, CG, Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation 136 (2017), 1989–1992.
    • (2017) Circulation , vol.136 , pp. 1989-1992
    • Varricchi, G.1    Galdiero, M.R.2    Tocchetti, C.G.3
  • 19
    • 85033784005 scopus 로고    scopus 로고
    • Survival after fulminant myocarditis induced by immune-checkpoint inhibitors
    • Arangalage, D, Delyon, J, Lermuzeaux, M, et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167 (2017), 683–684.
    • (2017) Ann Intern Med , vol.167 , pp. 683-684
    • Arangalage, D.1    Delyon, J.2    Lermuzeaux, M.3
  • 20
    • 85039050365 scopus 로고    scopus 로고
    • Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab
    • Nasr, F, El Rassy, E, Maalouf, G, et al. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. Eur J Cancer 91 (2018), 171–173.
    • (2018) Eur J Cancer , vol.91 , pp. 171-173
    • Nasr, F.1    El Rassy, E.2    Maalouf, G.3
  • 21
    • 85039950523 scopus 로고    scopus 로고
    • Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists
    • Frigeri, M, Meyer, P, Banfi, C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol 34 (2018), 92.e1–92.e3.
    • (2018) Can J Cardiol , vol.34 , pp. 92.e1-92.e3
    • Frigeri, M.1    Meyer, P.2    Banfi, C.3
  • 22
    • 84950117835 scopus 로고    scopus 로고
    • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    • Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
    • (2016) Lancet , vol.387 , pp. 1540-1550
    • Herbst, R.S.1    Baas, P.2    Kim, D.W.3
  • 23
    • 84953874197 scopus 로고    scopus 로고
    • Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
    • Sharabi, AB, Lim, M, DeWeese, TL, Drake, CG, Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
    • (2015) Lancet Oncol , vol.16 , pp. e498-e509
    • Sharabi, A.B.1    Lim, M.2    DeWeese, T.L.3    Drake, C.G.4
  • 24
    • 21144454783 scopus 로고    scopus 로고
    • Relation of acute pericardial disease to malignancy
    • Imazio, M, Demichelis, B, Parrini, I, et al. Relation of acute pericardial disease to malignancy. Am J Cardiol 95 (2005), 1393–1394.
    • (2005) Am J Cardiol , vol.95 , pp. 1393-1394
    • Imazio, M.1    Demichelis, B.2    Parrini, I.3
  • 25
    • 85045839872 scopus 로고    scopus 로고
    • Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
    • Tocut, M, Brenner, R, Zandman-Goddard, G, Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17 (2018), 610–616.
    • (2018) Autoimmun Rev , vol.17 , pp. 610-616
    • Tocut, M.1    Brenner, R.2    Zandman-Goddard, G.3
  • 27
    • 75649122868 scopus 로고    scopus 로고
    • CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis
    • Kamesh, L, Heward, JM, Williams, JM, et al. CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. Rheumatology 48 (2009), 1502–1505.
    • (2009) Rheumatology , vol.48 , pp. 1502-1505
    • Kamesh, L.1    Heward, J.M.2    Williams, J.M.3
  • 28
    • 85014388193 scopus 로고    scopus 로고
    • A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis
    • Langford, CA, Cuthbertson, D, Ytterberg, SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69 (2017), 837–845.
    • (2017) Arthritis Rheumatol , vol.69 , pp. 837-845
    • Langford, C.A.1    Cuthbertson, D.2    Ytterberg, S.R.3
  • 30
    • 17244363866 scopus 로고    scopus 로고
    • Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis
    • Salvarani, C, Cimino, L, Macchioni, P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53 (2005), 293–297.
    • (2005) Arthritis Rheum , vol.53 , pp. 293-297
    • Salvarani, C.1    Cimino, L.2    Macchioni, P.3
  • 31
    • 85053689477 scopus 로고    scopus 로고
    • Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
    • published online Sept 13.
    • Wang, DY, Salem, JE, Cohen, JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018 published online Sept 13. DOI:10.1001/jamaoncol.2018.3923.
    • (2018) JAMA Oncol
    • Wang, D.Y.1    Salem, J.E.2    Cohen, J.V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.